Should the U.S. Prohibit Reproductive Cloning?
By Tim Sandle,
Digital Journal
| 04. 18. 2014
[Quotes CGS's Marcy Darnovsky]
Untitled Document
Researchers have produced stem cell lines using somatic cell nuclear transfer (SCNT) from cells, making human reproductive cloning more technically feasible. Is this a good idea?
Not according to Marcy Darnovsky, PhD, executive director of the Center for Genetics and Society, a public interest organization based in Berkeley, California.
Talking to the Digital Journal, Darnovsky said: "No one wants to wake up to headlines that a rogue fertility doctor or scientist initiated a pregnancy with a cloned human embryo."
The Center for Genetics and Society (CGS) is a non-profit public affairs and policy advocacy organization working to encourage responsible uses and effective societal governance of human genetic and reproductive biotechnologies.
The basis of Darnovsky's concern relates to a study
published in the journal
Cell Stem Cell. In the journal, researchers report that they have produced stem cell lines using somatic cell nuclear transfer (SCNT) from cells taken from two adult men. The aim of this work is to produce patient-specific stem cells for medical treatments. But unlike induced pluripotent stem cells, which can also be patient-specific, SCNT...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...